SpineGuard Revenue Drops 19% in 2025 Amid US Restructuring
Event summary
- SpineGuard reported €3.758M in revenue for 2025, down 19% from 2024 due to US restructuring.
- Fourth-quarter revenue showed sequential growth of 13%, indicating resilience despite overall decline.
- US revenue dropped 24% year-over-year as SpineGuard transitions its business model under a strategic partnership with Omnia Medical.
- DSG® unit sales fell 11% to 5,482 units, with US sales accounting for 36% of total sales.
The big picture
SpineGuard's revenue decline reflects its strategic pivot in the US market, where it is transitioning to a partnership model with Omnia Medical. The company aims to improve operating margins through this restructuring, despite short-term revenue impacts. Broader industry trends highlight the growing importance of digital surgical guidance technologies, positioning SpineGuard for potential long-term gains if it can successfully navigate its current operational challenges.
What we're watching
- Operational Break-Even
- Whether SpineGuard can achieve operational break-even by the end of 2026 as it finalizes the sale of its US subsidiary to Omnia Medical.
- Strategic Partnerships
- The pace at which SpineGuard secures new strategic partnerships for expanding DSG® technology into surgical power tools, robotics, and dental applications.
- Geographic Growth
- How SpineGuard will offset declines in Latin America and the Middle East with continued growth in Europe and Asia.
Our editorial coverage:
Related topics